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Abstract 
 
The coagulation of blood is very important characteristics of the blood since it protects us from 
excess bleeding by forming clots and binding it. This is done by protein called fibrin stabilizing 
protein (XIIIB) and plays an important role in clot stabilization by crosslinking fibrin chains. 
However it has been found that these fibrin stabilizing factor also known as blood coagulation 
factor XIII is responsible for many cardiovascular diseases. But very little is known about the role 
of FXIII in vascular diseases. Although it showed increased levels of FXIII A-subunit antigen in 
patients with obliterative atherosclerosis of the lower limbs and in patients with diabetic 
angiopathy, small patient numbers make the interpretation of these data difficult. However, 
increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction has 
been described, assuming the presence of increased plasma FXIII plasma activity in patients with 
coronary artery disease. The research work aims to develop a novel lead molecule for coagulation 
factor XIIIB involved in cardiovascular diseases. The proposed work defines the protein structure, 
identifies the proposed ligands and develops the molecule by docking. 
Keywords: Blood, clot, Stabilizing, Cardiovascular, Coagulation factor, ligands, docking. 
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1 .  Introduct ion  and Object ive  
 
 
 
Cardiovascular systems consists of blood, heart and veins. Cardiovascular sickness (CVDs) 
are the class of infections that include veins and heart. The term cardiovascular sickness deals 
with any ailment that are linked with cardiovascular network such as hypertension, 
atherosclerosis, myocardial dead tissue, aneurysm and stroke. CVD is considered to be lead 
cause of death of 14 million people throughout the world (Mather 2006, Murray and Lopez 
1996, WHO 2002). In 1980-2003 the National Heart, Lung and Blood Institute (NHLBI) and 
Framingham Heart Study (FHS) assessed around 81,100,000 Indian adults to have one or more 
sorts of CVD. In India report of CVD death, rate of death is 34.3 percent, which is the very 
reason of death every year. (Nelson et al., 2006).  
Hypertension happens when blood goes through the vessels at a higher velocity than 
normal. Atherosclerosis is a condition of collection of oily materials including cholesterol, 
underneath the internal linings of blood vessels. Myocardial infarctions (MI), also called as 
heart attack, prompts degradation of a part of heart muscle due to a non-exposure to oxygen. 
Cerebrovascular accident (CVA) in like manner called as stroke, routinely occurs as somewhat 
cranial arteriole blasts or is hindered by an embolus (Thomas et al., 2000). Cardiac death is 
more found in smokers, an undesirable eating routine is a vital peril component for unending 
cardiovascular diseases (Maton et al., 1993). Fast food and refreshments containing colorants 
and added substances which are dangerous for the heart. Intake of excessive alcohol can induce 
hypertension, heart blocking, alcoholic cardiomyopathy and strokes. Drugs like heroin, cocaine 
and similar kinds cause choking in the heart valve and deteriorates the circulatory system. 
Family history also plays an essential factor in cardiovascular disease risk. The ordinary side 
effects of cardiovascular illness are related mainly with chest pain with shortness of breath. 
Individuals with coronary artery infection generally have steady movement of their symptoms 
over the long run. The seriousness or severity of symptoms increases as a vessel contracts over 
the long run. The indications of a stroke include: sudden weakening of the face, leg and arm 
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frequently on one side of the body, sudden complexity, inconvenience while talking or 
comprehension, eye, sudden trouble in strolling, wooziness, loss of balance or coordination, 
serious migraine with no known reason.  
The treatment of cardiovascular disease is based upon clinical history and physical 
examination of the patient. Supporting tests incorporate electrocardiography and estimation of 
the level of serum creatine kinase catalysts which are discharged into the blood by the injured 
tissue. Next technique is the heart imaging procedure which is called angiography (infusion of 
color into the vessels followed by X-rays). Lowering the pulse by decreasing the volume of 
blood pumped by the heart can be done by the beta-blockers such as propranolol (Inderal), 
metoprolol (Lopressor, Toprol), nadolol (Corgard) and atenol (Tenormin). These medications 
might likewise lessen the danger of a resulting heart attacks in patients who have endured once. 
Coagulation factor XIII B higher levels were seen during cardiovascular illness conditions 
(Bottenus et al., 1990). Over articulation of the protein Coagulation factor XIII B plasma 
prompts sicknesses like atherosclerosis, myocardial infarction (Lorand et al., 2001).  
Myocardial infarctions (MI) usually known as a heart attack, results from the interference 
of blood supply to a piece of the heart, resulting in the heart cells to die (Francis et al., 1980) . 
Due to impaired transglutaminase activity or a disproportionate increase of metalloproteinases 
may reduce the fibrous cap’s strength of an atheroma thereby increasing its vulnerability and 
favoring plaque rupture, a main cause of myocardial infarction (Devine et al., 1993). 
Dimethylbiguanide (metformin) interferes with factor XIII activation and with fibrin 
polymerization and atherosclerosis is caused (Shebusk et al., 1990). At the point when the 
illness is treated with metformin more than 3 months, factor XIII antigen and movement levels 
were diminished and it controls the illness (Ritchie et al., 2000).  
Computer aided drug design (CADD) utilizes computational science to find, upgrade, or 
study biologically active particles and molecules. The important part is the anticipation of the 
binding strength of a given molecule and its target. Consequently, ligand based virtual 
screening convention of CADD system was induced in the present study to propose potential 
inhibitors of Coagulation factor XIII B. Along these lines the present study was completed with 
the following aim and objectives. 
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1.1 Aim and Objectives of the Work 
The aim of the work can be determined as follows: 
 Designing novel lead molecules for human Coagulation factor XIII B involved in 
cardiovascular diseases. 
The objectives are as follows: 
1. Proteomic analysis of human Coagulation factor XIII B. 
2. Delineating Phylogenetic relationship of 30 selected human proteins causing 
cardiovascular disease. 
3. Metabolic pathway analysis. 
4. Ligand binding site prediction. 
5. Lead identification and optimization. 
 Ligand based virtual screening. 
 Docking and scoring using VLife software suite. 
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2 .  Literature Review 
 
 
The capacity of the body to control the stream of blood after vascular damage is very 
important to proceed with survival. The procedure of blood coagulating and after that the 
resulting disintegration of the coagulation, taking after repair of the damaged tissue, is termed 
hemostasis (Chung et al., 1974). Hemostasis made out of 4 noteworthy events that happen in 
a set request after the loss of vascular stability. The first step of the procedure is vascular 
constriction. This constrains the stream of blood to the area of damage. Next, platelets get 
enacted by thrombin and gather at the site of damage, forming an interim, free platelet plug 
(Nagy et al., 1980). Stimulating of platelet clumping is mainly done by a protein known as 
fibrinogen. Clumping of platelets occurs by tying to collagen that is exposed followed by 
rupture of endothelial covering of vessels (Muszbek et al., 1987). Nucleotide, ADP and the 
eicosanoid, TXA2, serotonin, phospholipids, lipoproteins, and different types of proteins 
imperative for coagulation cascade only after activation discharged by the platelets. Platelets, 
beside induced secretion can also change their shape in order to facilitate the formation of 
plug (Ando et al., 1987). Stability of the initial platelet plug is ensured by formation of a fibrin 
mesh (clot formation) and it surrounds the plug. At the end, the coagulation or the clot must 
be dissolved for blood stream to resume after tissue repair. The disintegration of the 
coagulation happens through the activity of plasmin (Hornyak et al., 1989). 
Intrinsic and extrinsic pathways lead to the development of fibrin coagulation (Muller 
et al., 1984). The two pathways merge on a typical pathway that prompts coagulation 
development even if their initiation mechanisms are different (Sakata et al., 1980). Both are 
complex pathways and include various distinctive proteins termed as clotting factor. Under 
typical physiological conditions fibrin clot formation is the most relevant event that occurs 
during hemostasis (Mosher et al., 1980). Most clinically significant is the initiation of the 
natural pathway by contact of the artery wall with lipoprotein particles, VLDLs and 
chylomicrons (Mimuro et al., 1986). 
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A much more stimulating goal is to develop an inhibitor for the chain in treatment of 
cardiovascular diseases, such as atherosclerosis, myocardial infarction (Morgan et al., 2007). 
A judicious and efficient way of inhibitor identification is high throughput virtual screening.  
Virtual Screening (VS) methods are fundamental part of the drug discovery system (Bajorath 
et al., 2002). Discovery of novel inhibitors (Umamaheswari et al., 2011) based on ligand based 
virtual screening method has been a great discovery. This methods precisely detects the small 
inhibitor property enabled molecules towards a target specific drug. 
  Blood coagulation factor XIII holds an important part in blood clotting and 
stabilization by crosslinking the fibrin chains (Ichinose et al., 1994). Blood coagulation XIII is 
basically a transglutaminase consisting two A and two B subunits rotating as a tetramer (A2B2) 
in the plasma (Yee et al., 1994). At around 21 μg/ml concentration, all A-subunit molecules 
are in complex with the B-subunit in the plasma while the B-subunit is in both free and complex 
forms. The overall concentration of B is about 21 μg/ml and nearly 50% of it freely circulates 
in plasma (10 μg/ml). Almost 90% of FXIII is attached to fibrinogen by a linking site for the 
B-subunit (Jujikawa et al., 1986) during circulation. Fibrinogen acts as a transporter for the 
zymogen plasma through this process. Activation peptide consisting of 37 amino acid is 
released after activation of FXIII to FXIIIA′. Dissociation of A′2B2 tetramer is facilitated in the 
presence of calcium. Both the phases (dissociation of the subunits and release of activation 
peptide) are important for the activation of the FXIII zymogen (Board et al., 1980) completely. 
In presence of fibrinogen the tetramer dissociation is increased and the activation peptide is 
released from the A-subunit which is enhanced by the proteolytic products of fibrinogen 
(polymerized des-A, des-A, B fibrinogen) (Dykes et al., 1987). When FXIII-catalyzed cross-
linked fibrin appears, this effect on the activation peptide is diminished. Activated factor XIII 
increases the mechanical toughness of the fibrin by catalyzing the covalent cross linking of 
the γ and α chains, and crosslinking the antiplasmin which increases its resistance to 
fibrinolysis. Some examples of proteins which form the substrates for factor XIII are factor 
FVII, fibronectin, α2-antiplasmin, thrombospondin, von Willebrand factor, collagen and 
vitronectin (Wilson et al., 1998). 
                  Factor XIII being a protransglutaminase, is activated by thrombin which catalyzes 
the formation of e-(cglutamyl) - lysine bonds in fibrin polymerization. Fibrin crosslinking 
reduces the clot mechanically, chemically as well as resilient to fibrinolysis [1, 2] (Kamath et 
al., 2003). FXIII is a heterotetramer consisting of two A and two B subunits that are associated 
non-covalently as A2B2 during the time of circulation [1, 2]. The A subunit has active site of 
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the enzyme (Kaptoge et al., 2003). Activation of FXIII is done by cleaving of the peptide bond 
among Arg37 and Gly38 of the A-subunit followed by B-subunit dissociation from the A-
subunit in presence of Ca2+ [3, 4]. Both the phases are essential in order to access the substrate 
to the catalytic triad of FXIII which are enhanced by the presence of the main substrate 
polymerized fibrin (Spencer et al., 2000). The B subunit is involved in equilibrium of the A-
subunit and has no enzymatic activity in the human plasma aqueous atmosphere [5, 6]. It 
consists of 641 amino acids divided into 10 cyclic repeats of about 60 amino acids each, which 
are called GPI structures or Sushi domains [7, 8]. Each of the Sushi domain is preset by a single 
exon. The function of these domains are thought to serve mainly as protein-binding module but 
is not yet known properly (H.P. Kohler, 1 February 1999) (Sinning et al., 2006). The A and B 
subunits of factor XIII interact as a complex in plasma, the genes that encode them reside on 
chromosomes 6p and 1q respectively, and are genetically unlinked. A Val34Leu polymorphism 
of the factor XIIIA gene located near the thrombin activation site has been associated with an 
altered rate of factor XIII activation, abnormal fibrin clot structure, and a decreased risk of 
arterial and venous thrombotic events. Komanasin recently identified a His95Arg 
polymorphism of the factor XIIIB gene that is related with an increased dissociation rate of the 
factor XIII A2B2 tetramer followed by activation by thrombin, but the role of His95Arg in 
arterial thrombosis has yet to be known.  
The dynamic site of the catalyst is contained in A-subunit and is incorporated by 
hepatocytes, monocytes, and megakaryocytes (Tzoulaki et al., 2007). The A-subunit flowing 
in plasma is taken from both liver and bone marrow is verified by protein phenotype analysis 
after bone marrow and liver transplantation. The B-subunit acts as a transporter for the reactant 
A-subunit in plasma, is arranged by the liver, and is emitted as a monomer that ties free A in 
plasma (Cremer et al., 2007). The A-subunit is isolated into 4 space (Robert A. S. Ariëns, 
August 1, 2002), assigned the catalyst center, barrel 1 and barrel 2. It contains an initiation 
peptide of 37 amino acids that forces the entrance of the substrate to the dynamic site cysteine. 
This structure is balanced out by a few hydrogen bonds and bridges of salt between the 
initiation peptide and the catalyst center of one subunit and the reactant center and barrel of the 
second subunit (Losner et al., 2003). While the A-subunit contains 6 potential asparagine-
connected glycosylation destinations, none of these have carb connections, as decided by 
recoloring with occasional corrosive Schiff base reagent14 or by mass spectrometry3 
interestingly, sugar adds to pretty nearly 8.5% of the aggregate sub-atomic weight of factor 
XIII B-subunit. The B-subunit is a protein made out of 10 repeated Sushi or glycoprotein-1 
domains. Each Sushi area contains 2 disulfide spans that manage its tertiary structure, adding 
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up to a sum of 40 cysteine deposits and 20 disulfide, connecting the B-subunit protein (Phear 
et al., 2001). The fundamental function of B-subunit is the adjustment and transport of the 
hydrophobic A-subunit in the human plasma environment (Levy et al., 2001). A substantially 
more difficult objective is to create inhibitor for the Coagulation element XIII B chain in 
treatment of cardiovascular sickness, for example, atherosclerosis, myocardial dead tissue 
(Morgan et al., 2007). An effective method for inhibitor distinguishing proof is high throughput 
virtual screening. Virtual screening (VS) methods play an essential role in the fields of drug 
research and discovery (Bajorath et al., 2002). One of the advancements in this field is 
exemplified with showed works performed in the field of ligand based virtual screening in 
disclosure of novel inhibitors against different illness (Umamaheswari et al., 2011). This 
procedure is time saving and in the meantime profoundly solid to recommend little atoms with 
sufficient resistance towards a predetermined medication target. 
The literature study revealed that there was no experimentally determined structure for 
human Coagulation factor XIII B. Therefore a reliable three dimensional model for the human 
Coagulation factor XIII B can be modelled using bioinformatics tools. As there is no specific 
inhibitor for human Coagulation factor XIII B and published inhibitor metformin obtained 
through literature search were used for ligand based high throughput virtual screening. 
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3 .  Methodology  
 
In this chapter, the software used and the process has been discussed. 
3.1 Retrieval of human coagulation factor XIII B sequence 
UniProt (Universal protein asset) is a store of protein information made by 
consolidating Swiss-Prot, TrEMBL and PIR. The UniProt involves the European 
Bioinformatics Institute (EBI), the Swiss Institute of Bioinformatics (SIB) and the protein 
information resource (PIR). It is the most essential database among all protein grouping 
databases (Leinonen et al., 2009). The UniProt Knowledgebase (UniProtKB) is the focal access 
area for broad curated protein data, comprising of capacity, arrangement and cross-references. 
Genome sequencing activities are the primary hotspot for UniProt. These proteins arrangement 
data accessible at UniProt hold the keys to get learning on some key elements on the medication 
targets which are basic for computer aided drug designing. UniProtKB Protein information 
base comprises of two segments SwissProt and TrEMBL. 
The protein sequence of human coagulation factor XIII B was retrieved from the UniProt 
accessed at http://www.uniprot.org 
 
 
3.2 Proteomic analysis of human coagulation factor XIII B 
Proteins are basically the polymers of L-alpha amino acids. Proteins fold into one or 
more particular spatial adaptations, determined by various non-covalent interactions, for 
example ionic interactions, van der Waals forces, hydrogen bonding and hydrophobic packing 
to perform their biological function (Durbin et al., 2006). Proteomic examination gives a 
premise to in silico portrayal of the protein towards physio-chemical properties, functional 
sites, secondary structural elements and structure function relationship.  
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The ExPASy or (expert protein analysis system) is a proteomics server of the Swiss Institute 
of Bioinformatics (SIB). It investigates protein arrangements and structures (Gasteiger et al., 
2003). The server capacities in a joint effort with the European Bioinformatics Institute. 
ExPASy additionally delivers the protein grouping knowledgebase, UniProtKB/Swiss-Prot and 
its computer aided supplement, UniProtKB/TrEMBL.  
 
Primary sequence analysis 
The primary structure of a protein consists of a linear chain of amino acids and peptide 
bonds connecting each residue. Number of online tools for performing primary structure 
analysis are available in ExPASy like ProtParam, ProtScale, SAPS (Statistical Analysis of 
protein Sequence) etc. 
ProtParam (Gasteiger et al., 2005) is a tool which allows computation of various physio 
chemical parameters for a given protein stored in Swiss-Prot or TrEMBL or for a user entered 
sequence. The computed parameters include the molecular weight, theoretical pI, amino acid 
composition, atomic composition, extinction coefficient, estimated half-life, instability index, 
aliphatic index and grand average of hydropathicity (GRAVY). 
 The protein sequence of human coagulation factor XIII B was submitted to ProtParam 
at http://www.expasy.ch/tools/ProtParam.html and results were analyzed. 
 
Prediction of functional elements 
Protein consists of functional parts such as motifs, patterns, domains and BLOCKS. 
Patterns are the conserved sequence of amino acids having characteristic trait of family. A 
motif is a nucleotide or amino acid sequence pattern that is vast and has, a biological 
significance where domain is referred as part of protein sequence and structure that can evolve 
the specific function. BLOCKS (Henikoff and Henikoff, 1996) are unspaced multiple 
alignment of segments of related protein sequences that relates to the most conserved regions 
of proteins. The database, for example, PROSITE, BLOCKS and Pfam were utilized to 
anticipate useful components from essential arrangement of the medication target. 
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Prediction of Pattern 
Uncharacterized proteins interpreted from genomic or cDNA arrangements are done by 
a database known as PROSITE (Bairach et al., 2002). With appropriate computational methods 
any biologically important patterns and sites can be identified along with its family. At times, 
the arrangement of an unknown protein is too remotely identified with any protein of known 
structure for recognizing its similarity by general grouping arrangement, yet it can be 
recognized by the event in its succession of a specific bunch of deposit sorts which is differently 
known as a signature, motif, pattern or fingerprint. These motifs arise as a result of specific 
necessities on the structure of particular regions of a protein which may be essential for their 
enzymatic movement. These necessities force tight imperatives on the development of those 
constrained (in size) however essential portions of a protein arrangement. The patterns are 
recognized by utilizing PROSITE database.       
  The protein sequence of human coagulation factor XIII B was submitted to PROSITE 
database (http://www.expasy.ch/prosite/) and the results were analyzed. 
 
Prediction of BLOCK 
The BLOCKS database is a collection of blocks representing known protein families 
that can be used to compare a protein of DNA sequence with documented families of protein. 
The blocks for the BLOCKS database are made usually by looking for most highly conserved 
regions in group of proteins documented in InterPro (Attwood et al., 2000). 
The protein sequence of human coagulation factor XIII B was submitted to BLOCKS 
database (http://blocks.fhcrc.org/blocks/blocks_search.html) and the results were analyzed. 
 
Prediction of Domain 
The Pfam (Eddy et al., 1997) database is a huge accumulation of protein families, each 
represented by multiple sequence alignments (MSAs) and hidden markov models (HMMs). 
Generally, proteins are made out of one or more functional groups called domains. Diverse 
mixes of domains offer ascent to the various scope of proteins found in nature. The capacity of 
a protein can be known by recognizable proof of their areas that happen inside of the protein. 
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There are two parts of Pfam: Pfam-A and Pfam-B. Pfam-A entries are high caliber, physically 
curated families. In spite of the fact that these Pfam-A entries cover a substantial extent of the 
arrangements in the basic grouping database, to give a more thorough scope of known proteins 
to create a supplement naturally utilizing the PRODOM database. These naturally produced 
entries are called Pfam-B. In spite of the fact that of lower quality, Pfam-B families can be 
helpful for distinguishing practically moderated districts when no Pfam-A sections are found. 
Pfam likewise creates more elevated amount groupings of related families, known as groups. 
A clan is an accumulation of Pfam-A sections which are connected by likeness of grouping, 
structure or profile-HMM. 
The protein sequence of human coagulation factor XIII B was submitted to Pfam 
database (http://pfam.sanger.ac.uk/search) and results were analyzed. 
 
3.3 Phylogenetic Analysis 
Phylogenetic analysis is the study of the evolutionary relationships among a group of 
related (nucleic acid or protein) sequences by producing a tree representation of the 
relationships known as phylogenetic tree. To construct a phylogenetic tree a multiple sequence 
alignment file of a group of 30 human cardiovascular disease causing sequences is needed. The 
various programs used for phylogenetic tree construction are PHYLIP, MEGA, PAML, TREE-
PUZZLE, DAMBE, Hennig86, RNA, NONA etc. 
 
Multiple sequence alignment 
Arranging three or more biological sequences, usually protein, RNA or DNA can be 
done by multiple sequence alignment (MSA). Ordinarily, the input set of query sequences are 
assumed to have shared a direct lineage. After doing the MSA, sequence homology can be done 
and phylogenetic analysis can be conducted to use the sequences shared on the basis of 
evolutionary origins. In order to assess sequence conservation of protein domains, tertiary and 
secondary structures and even individual amino acids or nucleotides multiple sequence 
alignment (MSA) is often used. 
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Phylogenetic tree construction 
A phylogenetic tree a fanning outline or "tree" demonstrating the induced 
transformative connections among different natural species or different substances based upon 
equalities and contrasts in their physical and/or hereditary attributes. In an established 
phylogenetic tree, every hub with relatives speaks to the surmised latest regular predecessor of 
the relatives and such detail is not present in an unrooted tree. The methods used for 
phylogenetic tree construction are: 
1. Maximum parsimony method -for a set of closely relates sequences. 
2. Maximum likelihood method -for a set of distantly related sequences. 
3. Distance matrix method -if the distance of relatedness relation is unknown or the 
sequences are moderately related. 
 
3.4 Pathway Analysis 
KEGG (http://www.genome.jp/kegg/) is a database of natural frameworks that 
incorporates genomic, synthetic and systemic useful data. KEGG gives a reference learning 
base to connecting genomes to life through the procedure of pathway mapping, which is to 
guide, for instance, a genomic or transcriptomic substance of qualities to KEGG reference 
pathways to derive systemic practices of the cell or the living being. Furthermore, KEGG gives 
a reference learning base to connecting genomes to nature, for example, for the examination of 
medication target connections, through the procedure of brite mapping. KEGG brite is a 
cosmology database speaking to useful progressive systems of different natural articles, 
including atoms, cells life forms, illnesses and medications, and connections among them. 
KEGG pathway is currently supplemented with another worldwide guide of metabolic 
pathways, which is basically a joined guide of around 120 current pathway maps. Also, littler 
pathway modules are characterized and put away in KEGG module that likewise contains other 
useful units and edifices. The KEGG asset is being extended to suit the requirements for 
reasonable applications. 
KEGG database was used to analyze role of human coagulation factor XIII B in 
metabolic pathway. 
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3.5 Homology modelling 
Homology modelling otherwise called comparative modelling is a class of technique 
for developing a model of a protein in atomic resolution from its amino acid succession (the 
"query sequence" or "target"). All homology modelling strategies depend on the distinguishing 
proof of one or more known protein structures (known as "templates" or "parent structures") 
liable to look like the structure of the query arrangement. The basic assumption of homology 
modelling is the unknown structure and the homologous template protein of known structure 
have nearly identical backbone structure in the aligned regions. Homology modelling may also 
be used in CADD when a good template structure is available for the target sequence. 
Homology modelling is used only when the target sequence have >30% identity with the 
template sequence. On production of an alignment that maps residues in the query sequence to 
residues in the template sequence a model can be generated using different software making 
the alignment as input file. 
 
3.6 3-D structure prediction of coagulation factor XIII B protein 
The knowledge of the three-dimensional structure is a requirement for experimental 
approach. Structural information often greatly enhances our understanding of how proteins 
function and how they interact with each other. X-ray crystallography, NMR spectroscopy, and 
Electron Microscopy are the ways to obtain detailed structural information. But, all these 
techniques involve elaborate technical procedures and many proteins fail to crystallize at all 
and/or cannot be obtained or dissolved in large enough quantities for NMR measurements. The 
size of the protein is also a limiting factor for NMR. Therefore when structural information 
regarding a protein is not available from these experimental procedures rely on computational 
modeling to identify the tertiary structure of the protein. The computational modeling for 
structure prediction includes Homology modeling, threading and ab initio methods. Homology 
modeling is widely used procedure of aligning target and template to generate a model. 
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3.7 Input data for Homology Modelling 
 Target sequence. 
 Template sequence. 
 Alignment of target and template sequence. 
 Structure alignment of multiple templates, if available. 
 Experimental information. 
Modeller is open source software used for protein modelling. SGI Fuel Workstation 
with 2.6 GHz processor, 8GB RAM, 750 GB Hard drive and an Nvidia GeForceGT 540M 
graphics card running in Windows 7 operating system was set as experimental environment for 
the present study. Bioinformatics software such as Modeller9v8 (Eswar et al., 2008; Sali and 
Blundell, 1993), and online resources were employed systematically to propose the outcome 
of the study. 
 
3.8 Modelling of the unknown protein 
Modeller 9.14 
Modeller is a computer program that models three-dimensional structures of proteins 
and their assemblies by satisfaction of spatial restraints (Sali and Blundell, 1993). The distance 
and dihedral angle restraints on the target sequence are calculated from its alignment with 
template 3D structure. The form of these restraints was obtained from a statistical analysis of 
relationship between many pairs of homologous structures. This analysis relied on a database 
of 105 family alignments that include 416 proteins with known 3D structure (John and Sali, 
2003). A 3D model is obtained by optimization of a molecular probability density function 
(pdf). The molecular pdf for comparative modeling is optimized with the variable target 
function procedure in Cartesian space that employs methods of conjugate gradients and 
molecular dynamics with simulated annealing.  
Modeller can also perform multiple comparisons of protein sequences and/or structures, 
clustering of proteins, and searching of sequence databases. Modeller is most frequently used 
for homology or comparative protein structure modeling. The user provides an alignment of a 
sequence to be modeled with known related structures and modeller will automatically 
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calculate a model with all non-hydrogen atoms. Modeller9v8 is the latest version and is 
currently maintained by BENWEBB, California University, and Sanfransisco, U.S.A. 
Template identification:  A template is the one which has >30% identity with the target or 
query sequence to build a reliable model. More the identity more will be the accuracy of the 
model. Template can be identified using BLASTP search. 
BLAST: Basic local alignment search tool (BLAST) is a sequence similarity search tool. 
BLAST (Altschul et al., 1990) is available from http://www.ncbi.nlm.nih.gov/blast.  
BLAST at NCBI has been recently re-engineered to improve usability and performance 
(Johnson et al., 2008), it compares all combinations of protein or nucleotide queries with 
nucleotide or protein database. There are different flavors of BLAST like Blastp, Blastn, 
Blastx, tBlastn, and tBlastx. Of which Blastp is uses query protein sequence and searches for 
similarity in the protein database. Blastp was used to find the template sequence. 
 The human coagulation protein was queried against protein databank (PDB) using 
BLASTP to identify the template structure.  
Model generation 
 Modeller 9.14v was used for generating a 3 dimensional model coagulation factor 
XIII B chain protein. Modeller builds the model based on homology modeling, it requires three 
files those are Alignment file, PDB or Atomic file and Script file. Solution structure of the c-
terminal SCR-16/20 fragment of complement factor H of human was taken as template 
sequence (having PDB ID 2QFH). 
Alignment file contain sequence alignment of target and template, this file should have an 
extension ‘*.ali’. The resulted PIR file generated by ClustalX was modified as below and saved 
as ‘qsec1.ali’. 
P1;P05160 
sequence:P05160:1:A:661:A:::: 
MRLKNLTFIIILIISGELYAEEKPCGFPHVENGRIAQYYYTFKSFYFPMS 
IDKKLSFFCLAGYTTESGRQEEQTTCTTEGWSPEPRCFKK--CTKPDLSN 
GY-ISDVKLLYKIQENMRYGCASGYKTTGGKDEEVVQCLSDGWSSQPTCR 
KEHETCLAPELYNGNYSTTQKTFKVK--DKVQYECATGYYTAGGKKTEEV 
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ECLTYGWSLTPKC--TKLKCSSLRLIENGYFHPVK-QTYEEGDVVQFFCH 
ENYYLSGSDLIQCYNFGWYPESPVCEGRRNRCPPPPLPINSKIQTHS-TT 
YRHGEIVHIECELNFEIHGSAEIRCEDGKWTEPPKCIEGQEKVACEEPPF 
IENGAANLH----SKIY-YNGDKVTYACKSGYLLHGSN---EITCNRGKW 
TLPPECVENNENCKHPPVVMNGAVADGILASYATGSSVEYRCNEYYLLRG 
SKISRCEQGKWSSPPVCLEPCTVNVDYMNRNNIEMKWKYEGKVLH--GDL 
IDFVCKQGYDLSPLTPLSELSVQCNRGEVKYPLCTRKESKGMCTSPPLIK 
HGVIISSTVDTYENGSSVEYRCFDHHFLEGSREAYCLDGMWTTPPLCLEP 
CTLSFTEMEKNNLLLKWDFDNRPHILHGEYIEFICRGDTYPAELYITGSI 
LRMQCDRGQLKYPRCIPRQSTLSYQEPLRT 
* 
>P1;2QFHa 
StructureN:2QFHa:935:A:1226:A:::: 
---------------------------PEISHGVVAHMSDSYQ------- 
YGEEVTYKCFEGFGIDG---PAIAKCLGEKWSHPPSCIKTDCLSLPSFEN 
AIPMGEKKDVYKAGEQVTYTCATYYKMDGASN---VTCINSRWTGRPTCR 
--DTSCVNPPTVQNAYIVSRQMSKYPSGERVRYQCRSPYEMFGD---EEV 
MCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQ 
NLYQLEGNKRITCRNGQWS-EPPKCL--HPCVISRE--IMENYNIALRWT 
AKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKLEYP-------- 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
------------------------------------------ 
* 
>P1;2QFHb 
StructureN:2QFHb:929:A:1231:A:::: 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
----------LPCKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGP 
AIAKCLGEKWSHPPSCI----KTDCLSLPSFENAIPMGEKKDVYKAGEQV 
TYTCATYYKMDGASNVTCINSRWTGRPTCRD----TSCVNPPTVQNAYIV 
SRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCG 
PPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNKRITCRNGQWSEP 
PKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSR 
S--HTLRTTCWDGKLEYPTCAKR 
* 
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>P1;2QFHc 
StructureN:2QFHc:924:A:1231:A:::: 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
-------------------------------------------------- 
-----------------------------EAEFGLPCKSPPEISHGVVAH 
MSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTD--CLSL 
PSFENAIPMGEKKDVYKAGEQVTYTCATYYKMDGASNVTCINSRWTGRPT 
CRDTSCVNPPTVQ--NAYIVSRQMSKYPSGERVRYQCRSPYEM-----FG 
DEEVMCLNGNWTEPPQC--KDSTGKCGPPPPIDNGDITSFPLSVYAPASS 
VEYQCQNLYQLEGNKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRW 
TAKQKLYSRTGESVEFVCKRG---YRLSSRSHTLRTTCWDGKLEYPTCAK 
R* 
 
Script file is a program file written in python script. The alignment file, known protein 
structure name and unknown sequence name was set as they were kept in alignment file. Other 
requisite parameters were set properly and the file was saved as “qsec1.py” script file was 
prepared to generate 20 models for coagulation factor XIII B chain with dope score. 
 
Running Modeller: The script file (qsec1.py) was executed using Modeller command 
prompt. The model with lowest score was chosen for later validation and docking studies.  
Validation of modelled protein structure 
The three dimensional structure obtained using Modeller can be validated using 
validation servers like WHATIF and PROCHECK. 
The PROCHECK analysis provides an idea of stereo-chemical quality of all protein 
chains in a given PDB structure. They highlight regions of proteins which appear to have 
unusual geometry and provide an overall assessment as the structure as a whole. 
 
 
21 | P a g e  
 
The stereo chemical validation of model structure of proteins is an important part of 
molecular modeling. Firstly, the selection of high quality structures for inclusion in loop 
dictionaries is important for the simple reason that these coordinate sets will be used to build 
future models. Secondly, the structure evaluation of comparative modeling output must be used 
to identify possible problematic regions. It is good to use verification tool for refinement which 
will improve quality of new structures and probably make structure validation easier.  
The RCSB Validation Server allows to check the format of coordinate and structure 
factor files and to create a variety of validation reports about the structure. The aim of 
PROCHECK is to assess how normal, or conversely how unusual the geometry of the residues 
in a given protein structure is, as compared with stereo-chemical parameters derived from well- 
refined high resolution structures. This also validates protein structure by calculating covalent 
geometry, Planarity, Dihedral angles, Chirality, Non-bonded interactions, Main-chain 
hydrogen bonds, Disulphide bonds, Stereochemical parameters and Parameter comparisons 
etc. 
PROCHEK was accessed from http://www.rcsb.org/pdb/home/home.do. Deposit and 
validate option was selected, X-ray method was selected and then by selecting the options PDB 
and validate, Ramachandran plot was analyzed. 
 3.9 Lead identification 
         Ligand based high-throughput virtual screening: 
The smile formats for the existed ligand were submitted to Ligand Info database at 
http://ligand.info/ to produce the library of chemical compounds. The smile format for these 
three ligands were generated using Molinspiration cheminformatics (JME Molecular Editor). 
The Ligand-Info framework is in view of the supposition that little particles with 
comparative structure have comparable practical (binding) properties. The created framework 
empowers a quick and sensitive record based quest for comparable mixes in substantial 
databases. A Java-based device for grouping and checking of little molecules has been made. 
The instrument can intuitively gather sets of molecules and make file profiles on the client side 
and consequently download comparable atoms from a database of 250000 mixes. The 
published inhibitor (metaformin) of human protein was searched through pubmed, pubchem 
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and literature search and submitted to Ligand. Info Meta- Database to prepare an in house 
library of many compounds from more than one million entries (Umamaheswari et al., 2010a; 
Umamaheswari et al., 2010b; Grotthuss et al., 2003). The framework is accessible at 
http://Ligand.Info. The application requires the Java Runtime Environment 1.4, which can be 
automatically installed during the first use on desktop systems. A standalone version of the 
program is available from the authors upon request. 
Virtual screening (VS) is a computational procedure utilized as a part of medication 
disclosure research. It includes the fast in silico appraisal of expansive libraries of substance 
structures to distinguish those structures that bind the drug target mostly, commonly a protein 
receptor or chemical (Rollinger, Stuppner and Langer, 2008). The purpose of virtual screening 
to come up with hits of novel chemical structure that bind to the macromolecular target of 
interest. Hence, accomplishment of a virtual screen is characterized as far as discovering new 
platforms as opposed to numerous hits. Interpretations of virtual screening accuracy should 
therefore be considered with caution (Sun, 2009). Low hit rates of scaffolds are clearly 
preferable over high hit rates of already known scaffolds. There are two broad categories of 
screening techniques: ligand-based and structure-based (McInnes, 2007). 
3.10 Computational docking 
 Docking is a system which predicts the favored introduction of one particle to a second 
when bound to one another to frame a steady complex (Lengauer et al., 1996). In the field of drug 
designing configuration, first particle is normally protein while the second one is small organic 
molecule, potential drug target is utilized to anticipate the quality of affiliation or binding affinity 
between two molecules using for example scoring functions. Hence, docking plays an important role 
in the rational drug design (Kitchen et al., 2004). A number of powerful software programs, e.g.  
VLifeDock, Schrodinger software (Glide), Auto Dock, HEX, GOLD, FlexX, DOCK, Surflex, 
LigandFit, have been developed over the past several decades to carry out the docking. 
VLifeDock: 
 VLifeDock provides its users with a choice of methods for molecular docking. Grid 
based docking, GA docking and VLife's own GRIP docking are the three methods that offer 
unique 'Accuracy - Speed' options to the user from rapid screening to complete precision 
docking. VLifeDock also has batch docking facility to enable prioritizing the ligands based on 
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their binding scores easily. The choice of systematic and stochastic methods with an array of 
scoring functions makes VLifeDock a truly versatile application. VLifeDock is available for 
both Linux and Windows® operating systems. The docking score and binding orientations of 
the proposed leads, and known coagulation factor XIII B chain ligand were compared to 
validate the docking predictions. 
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Chapter – 04 
RESULTS AND DISCUSSION  
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4. Results and discussion 
 
 
4.1 Retrieval of FXIII B human sequence 
The protein sequence for human Coagulation factor FXIII B was aquired from UniProt. The 
Fasta sequence was displayed in table 1. 
 Table1. Sequence of human FXIII B retrieved 
>sp|P05160|F13B_HUMAN Coagulation factor XIII B chain OS=Homo sapiens GN=F13B PE=1 SV=3 
MRLKNLTFIIILIISGELYAEEKPCGFPHVENGRIAQYYYTFKSFYFPMSIDKKLSFFCL 
AGYTTESGRQEEQTTCTTEGWSPEPRCFKKCTKPDLSNGYISDVKLLYKIQENMRYGCAS 
GYKTTGGKDEEVVQCLSDGWSSQPTCRKEHETCLAPELYNGNYSTTQKTFKVKDKVQYEC 
ATGYYTAGGKKTEEVECLTYGWSLTPKCTKLKCSSLRLIENGYFHPVKQTYEEGDVVQFF 
CHENYYLSGSDLIQCYNFGWYPESPVCEGRRNRCPPPPLPINSKIQTHSTTYRHGEIVHI 
ECELNFEIHGSAEIRCEDGKWTEPPKCIEGQEKVACEEPPFIENGAANLHSKIYYNGDKV 
TYACKSGYLLHGSNEITCNRGKWTLPPECVENNENCKHPPVVMNGAVADGILASYATGSS 
VEYRCNEYYLLRGSKISRCEQGKWSSPPVCLEPCTVNVDYMNRNNIEMKWKYEGKVLHGD 
LIDFVCKQGYDLSPLTPLSELSVQCNRGEVKYPLCTRKESKGMCTSPPLIKHGVIISSTV 
DTYENGSSVEYRCFDHHFLEGSREAYCLDGMWTTPPLCLEPCTLSFTEMEKNNLLLKWDF 
DNRPHILHGEYIEFICRGDTYPAELYITGSILRMQCDRGQLKYPRCIPRQSTLSYQEPLRT* 
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   4.2     Proteomic analysis of human FXIII B 
 Primary sequence analysis: 
  FXIII B contains 661amino acids with a molecular weight of 75510.6 Daltons. The 
Isoelectric point value is 6.01 the total number of positively and negatively charged residues is 
83 and 73 respectively. Aliphatic index is 65.60 and grand average of hydropathicity (GRAVY) 
was -0.551. The physio-chemical parameters, amino acid and atomic compositions of FXIII B. 
 
 Table 2. Predicted physio-chemical parameters of human FXIII B through ProtParam 
S.No Physico-chemical Property 
 
Values 
1. Number of Amino Acids 661 
2. Molecular weight  75510.6 
3. Total number of positively charged 
residues(Arg+Lys) 
                       83  
4. Total number of negatively charged 
residues(Asp+Glu) 
                         73 
5. Theoretical pI 6.01 
6. Formula          
C3343H5111N885O1013S50 
 
7. Total  number of atoms 10402 
8. Instability index                       46.13 
9. Aliphatic index                        65.60 
10. Grand average of hydropathicity (GRAVY) -0.551 
 
 
Aliphatic index is the relative volume occupied by aliphatic side chains like alanine, 
valine, isoleucine and leucine, which is regarded as a positive factor for the increase of 
Thermo stability of globular proteins. GRAVY (Grand average of hydropathicity index) 
shows the solubility of the proteins: positive GRAVY (hydrophobic), negative GRAVY 
(hydrophilic). As the GRAVY value is -0.551, it indicates that the molecule is hydrophilic. 
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 Table 3. Amino acid composition of human FXIIIB predicted through ProtParam 
Amino acid  Composition
Ala (A)  18    2.7% 
Arg (R)  28    4.2% 
Asn (N)  31    4.7% 
Asp (D)  22    3.3% 
Cys (C)  40    6.1% 
Gln (Q)  20    3.0% 
Gly (G)  49 9.2% 
Gly (G)  49 7.4% 
His (H)  17    2.6% 
Ile (I)  34  5.1% 
Leu (L)  51    7.7% 
Lys (K)  45    6.8% 
Met (M)  10   1.5% 
Phe (F)  21    3.2% 
Pro (P)  41    6.2% 
Ser (S)  46    7.0% 
Thr (T)  45    6.8% 
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Prediction of functional elements of human FXIII B: 
 The human FXIII B sequence was scanned against PROSITE patterns and profiles, 
which showed the patterns along with their ID’s and sites. BLOCKS database was used to 
find the conserved regions and Pfam for the domains of the protein. 
 
Pattern prediction: 
 The use of protein sequence patterns or motifs to determine the function of proteins 
is an essential tool of sequence analysis. Significant patterns are not found in FXIII B. 
  
Trp (W)  10   1.5% 
Tyr (Y)  43    6.5% 
Val (V)  29    4.4% 
Pyl (O)   0    0.0% 
Sec (U)   0    0.0% 
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BLOCKS prediction: 
 The possible hits (motif) reported through BLOCKS database for FXIII B are 2. The 
first hit with ID IPB000436, with protein name Sushi domain/SCR domain/CCP module, 3of 
3 blocks were observed with 1.3e-06 Value indicating that it is most significant match. ID of 
the second hit is IPB005533, with protein name AMOP domain 1 of 16 blocks were observed 
with 0.0005 E-value indicating that is less significant. 
 
Table 4. Prediction of BLOCKS regions 
PREDICTION No. OF HITS  
FAMILY 
 
BLOCKS 
COMBINED 
E-VALUE 
 
 
FXIII B 
 
 
 
 
 
 
 
         2   
  Sushi   
domain/SCR 
domain/CCP 
module 
 
AMOP domain 
 
    
   3 of 3 
 
  1 of 16 
 
 
     1.3e-06 
 
 
       0.0005   
 
Pfam: 
            Human, coagulation factor XIII B chain has three significant matches of pfam-A and 
no match with pfam-B. The pfam-A matches was shown in table 5. 
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 Table 5: pfam-A matches for FXIII B   
 
Source Name Start End 
Pfam      Sushi 
     Sushi 
     Sushi      
     Sushi 
     Sushi 
     Sushi     
     Sushi 
 
25 
91 
153 
213 
274 
336 
524 
87 
146 
208 
267 
327 
389 
578 
 
4.3   Phylogenetic analysis of protein 
Multiple sequence alignment: 
The Multiple sequence alignment is performed for FXIII B and other 29 cardiovascular 
causing proteins using ClustalW. The 30 cardiovascular disease causing proteins and their 
corresponding UniProt are shown in the table 6. 
Table 6. List of 30 cardiovascular disease causing proteins with their UniProt IDS. 
S.No                           Protein names Uniprot IDS 
1       Complement component c8 alpha chain P07357 
2                    Cathepsin D P07339 
3             Macrophage colony stimulating factor 1 receptor P07333 
4             Growth factor receptor bound protein-2 P62993 
 
 
31 | P a g e  
 
5                     Ficolin-3 O75636 
6              Sulphydryl oxidase-1 O00391 
7                Heparin cofactor-2 P05546 
8            Apolipoprotein A-1 PO2647 
9            Insulin like growth factor binding protein -1 P08833 
10                 Alpha -1 acid glycoprotein 1 P02763 
11      Peptidyl-prolyl cis trans isomerase F mitochondrial P30405 
12            Coagulation factor XIII B chain P05160 
13                 Collagen alpha -1(1) chain P02452 
14     Neutrophil gelatinase-associated lipocalin(NGAL) P80188 
15         Peptidyl-prolyl cis-trans isomerase A(PPIA) P62937 
16                  CD5 antigen-like(CD5L) O43866 
17         Retinol-binding protein 4(RET 4) P02753 
18  Insulin-like growth factor-binding protein 2(IBP2) P18065 
19 Leukocyte immunoglobulin-like receptor subfamily A 
member 
Q8N6C8 
20        Non-secretory ribonuclease(RNAS2) P10153 
21  Insulin-like growth factor-binding protein 6(IBP6) P24592 
22 Insulin-like growth factor II(IGF2) P01344 
23  Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1(PIN 
1) 
Q13526 
24                   Myotrophin(MTPN) P58546 
25                Ribonuclease pancreatic(RNAS 1) P07998 
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26          Monocyte differentiation antigen CD14(CD14) P08571 
27                  cDNA FLJ78607(A8KAM9) A8KAM9 
28                 CD59 glycoprotein(CD59) P13987 
       29       Insulin-like growth factor-binding protein 4(IBP4) P22692 
      30              Beta-2-microglobulin(B2M) P61769 
 
    Multiple sequence alignment was done by using ClustalW for phylogenetic tree 
construction. 
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Phylogenetic tree construction: 
 
 The phylogenetic tree was checked in ClustalW website accessed at www.ebi.ac.uk 
after completing the multiple sequence alignment.  
 .  
 Figure. 1 Rooted tree for FXIII B and 29 cardiovascular disease causing proteins  
Figure. 1 shows that FXIII B (p05160) and CD5 antigen-like (O43866) are much 
closely related. All the above 30 proteins are the cardiovascular causing proteins. So this tree 
also reveals that the human coagulation protein belongs to the family of the cardiovascular 
disease causing proteins. 
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4.4    Pathway analysis 
The complement and coagulation cascades pathway in which the FXIII protein is involved 
was retrieved from KEGG Database. The complement and coagulation cascades pathway and 
the position of the FXIII are shown in the figure 2. 
. 
       Figure 2. Complement and coagulation cascade Pathway 
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4.5    Three dimensional structure prediction of human FXIII B 
 The human coagulation factor XIII B protein was queried against PDB using 
BLASTP. Chain Solution structure of the c-terminal SCR-16/20 fragment of complement 
factor H of human was taken as template sequence (having PDB ID 2QFH). The structure of 
template was downloaded from PDB. The alignment file was generated using ClustalW. 
Alignment file, PDB file of template with were initialized in the modeller script file. The 
program saved as “tseq1.py” (script file) was run through Modeller to generate model for 
human coagulation factor XIII B protein. 
 
   Figure 3. 3D structure of the XIIIB protein 
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4.6    Lead identification 
Ligand based high-throughput virtual screening: 
 The active site residues are ILE-9 which was searched through literature for structure 
based virtual screening from the 1151 compounds of in house ligand library. LigPrep was used 
to generate multiple conformations (toutomers, sterioisomers) 2561 compounds of in house 
library to dock into binding site generated for virtual screening. 
4.7    Docking Studies 
The conformations after filtering for ADME (absorption, distribution, metabolism, 
excretion) properties and reactive functional group was subjected to docking procedure those 
uses softer to high precision penalty to steric classes, were followed subsequently. 6 lead 
molecules were selected based on lower G score through virtual screening. Docking is done 
using VLife software. All the 6 lead molecules were subjected to docking with the receptor 
protein human coagulation factor XIII B. Structures of 6 lead molecules generated through 
virtual screening were shown in figure below. 
Analysis of docking complex based on docking scores revealed that the six leads 
showed good binding affinities towards human coagulation factor XIII B. Among the six leads 
two leads have better docking score than that of metaformin and it also has good capability of 
interacting with the ligand binding site. Hence, in the present study two leads were proposed 
as potential inhibitors against human coagulation factor XIII B. The highest binding affinity 
and the least docking score of -5.321 Kcal/mol was observed as a best lead than that of 
metaformin with the docking score of -5.239 Kcal/mol.  The structures of six proposed leads 
with their docking scores were shown in figure 4. 
 
 
37 | P a g e  
 
 
    Figure 4. Structures of six proposed lead 
 Arg-34, Glu-31, Thr-7 residues were involved in formation of hydrogen bond 
network. Out of the 6 lead molecules, the lead ‘1’, having the least docking score of -5.21 was 
taken. The docking complex of human coagulation factor XIII B with lead ‘1’ molecule and 
the hydrogen bonds formed by lead ‘1’ molecule with human coagulation factor XIII B were 
given in figure5 respectively. The amino acid residues involved in binding with the lead 1 were 
Title: lead1 
Score: ‐5.32 
Title: lead2 
Score: ‐5.27 
Title: lead3 
Score: ‐4.64 
Title: lead4 
Score: ‐4.17 
Title: lead5 
Score: ‐2.63  Title: lead6 Score: ‐3.81 
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similar to the residues predicted at the binding site which evidences the correct prediction in 
sequence analysis. 
. 
 
 
       Figure 5. Docking complex of human coagulation factor XIII B with lead ‘1’ molecule. 
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Figure 6. Docking interactions of lead ‘1’ molecule with the human coagulation factor XIII B. 
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4.8     Prediction of ADME properties  
The physically significant descriptors and pharmaceutically relevant properties of 
inhibitors, were molecular weight, H-bond donors, H-bond acceptors, log P (octanol/water), 
log PMDCK, log Kp (skin permeability), human oral absorption and their position according 
to Lipinski’s rule of 5 were analysed. Lipinski’s rules of 5 is a rule of thumb to evaluate drug 
likeness, or determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The rule 
describes molecular properties important for drug’s pharmacokinetics in the human body 
including its ADME. However the rule does not predict if a compound is pharmacologically 
active (Lipinski 2001). Based on Lipinski’s rule of 5 the two leads which were proposed have 
showed allowed values for the properties analysed and exhibited drug-like characteristics, and 
also has good pharmacological properties. Among the proposed leads, the lead 1 molecule with 
the lowest docking score effectively binds with coagulation factor XIII B and blocks the 
functional activity.  Human coagulation factor XIII B up regulation was observed in 
atherosclerosis, myocardial infarction etc. The lead 1 molecule can regulate the elevated levels 
of coagulation factor XIII B efficiently during the cardiovascular disease condition. 
 
Table 7. Principle descriptors of six leads using QikProp3.2 
Lead 
no. 
MW rot
or 
dipo
le 
SASA FOSA FISA PISA WPSA PSA volume don
orH
B 
accp
tHB 
IP 
(eV) 
EA 
(eV) 
glob 
                
1 251.2 4 6.3 486.9 0.00 162.4 337.1 0.00 115.8 828.0 5.00 2.2 8.1 0.4 0.85 
2 282.3 5 6.3 499.6 92.7 180.9 258.0 0.00 79.8 891.6 5.00 4.5 8.4 0.7 0.84 
3 
4 
5 
6 
252.2 
253.2 
307.3 
253.2 
4 
4 
11 
3 
4.5 
9.4 
5.0 
10.4 
531.8 
497.0 
489.7 
534.3 
0.00 
0.00 
175.4 
0.00 
188.2 
199.8 
296.1 
220.7 
308.8 
289.9 
0.00 
266.1 
0.00 
0.00 
62.9 
0.00 
101.2 
95.4 
104.4 
189.5 
891.2 
804.8 
917.7 
800.3 
5.00 
5.00 
4.5 
4.0 
 
3.7 
4.7 
8.0 
4.5 
8.4 
8.4 
9.7 
8.4 
0.4 
0.7 
0.3 
0.8 
0.85 
0.85 
0.85 
0.85 
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The abbreviations used to specify different principal descriptors of ten probable leads in the 
table and their range in 95% of the available drugs are given. The Range for properties of 
95% drug is given based on QikProp3.2.  
(Range 95% of Drugs) 
MW = Molecular Weight            (130.0 / 725.0) 
Rotor=No. of Rotatable Bonds     (0.0 / 15.0) 
Dipole=Dipole Moment      (   1.0 / 12.5) 
SASA =Total solvent accessible surface area        (300.0 /1000.0) 
FOSA =Hydrophobic solvent accessible surface area  (   0.0 / 750.0) 
FISA =Hydrophilic solvent accessible surface area   (   7.0 / 330.0) 
PISA =Carbon Pi solvent accessible surface area   (   0.0 / 450.0) 
WPSA=Weakly Polar solvent accessible surface area  (   0.0 / 175.0) 
PSA=vdW Polar surface area      (   7.0 / 200.0) 
Volume=Molecular Volume (A^3)          (500.0 /2000.0) 
Donor= Donor -    Hydrogen Bonds                (   0.0 /   6.0) 
AccptHB= Acceptor - Hydrogen Bonds    (   2.0 / 20.0) 
IP (eV) =Ionization Potential      (   7.9 / 10.5) 
EA (eV) =Electron Affinity         (-0.9 /   1.7) 
Glob=Globularity       (0.75 / 0.95) 
 
   Table 8. ADME properties of proposed two leads using QikProp 3.2 
Lead 
no. 
log 
o/w 
logs Clogs logBB logKp logKhsa PMDCK PCaco %human 
oral 
absorption 
Rule 
OfFive 
Rule 
Of 
Three 
1 1.8 -2.8 -3.7 -1.1 -5.0 -0.2 127.5 285.3 81.5 0 0 
2 1.3 -3.0 -3.7 -1.4 -5.5 -0.3 82.3 190.3 75.4 0 0 
3 
4 
5 
6 
1.1 
0.6 
-2.3 
0.7 
-3.0 
-3.7 
-2.5 
-2.8 
 
-2.7 
-3.3 
-3.1 
-3.3 
-1.4 
-1.5 
-2.2 
-1.6 
-5.8 
-7.9 
-6.4 
-5.0 
-0.3 
-0.4 
-1.4 
-0.3 
69.4 
52.7 
0.2 
32.2 
162.5 
126.2 
0.104 
79.8 
73.0 
68.3 
0.00 
65.2 
0 
0 
1 
0 
0 
0 
2 
0 
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(Range 95% of Drugs) 
 
LogP o/w = log P for octanol/water     (-2.01 /   6.5)  
LogS= log S for aqueous solubility        (-6.53 /   0.5) 
CIlogS= log S - conformation independent                 (-6.55 /   0.5) 
LogBB= log BB for brain/blood             (-3.03/   1.2) 
Log KP = log KP for skin permeability     (KP in cm/hr) 
Log Khsa= log K hsa Serum Protein Binding        (-1.51 /   1.51) 
Lipinski Rule of 5 Violations               (maximum is 4) 
Jorgensen Rule of 3 Violations              (maximum is 3) 
% Human Oral Absorption in GI (+-20%)     (<25% is poor) 
Apparent Caco-2 Permeability (nm/sec)            (<25 poor, >500 great) 
Apparent MDCK   Permeability (nm/sec)      (<25 poor, >500 great) 
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5  .  Summary  and Conc lus ion  
 
 
This chapter concludes the technical sum-up of the thesis work on Designing novel lead 
molecules for human Coagulation factor XIII B involved in cardiovascular diseases. 
5.1  Summary 
Blood coagulation factor XIII (likewise called fibrin-stabilizing component) assumes 
an imperative part in cluster adjustment by cross connecting fibrin chains. Factor XIII (FXIII) 
was found more than 70 years back and studies showed the insolubility of fibrin clusters in the 
vicinity of calcium. Blood coagulation FXIII is a transglutaminase made out of two A- and two 
B-subunits circling in plasma as a tetramer (A2B2). The B-subunit serves as a transporter for 
the catalytic A-subunit in plasma, is incorporated by the liver, and is emitted as a monomer that 
ties free A in plasma. The A-subunit is partitioned into 4 spaces, assigned the _-sandwich, the 
catalytic center, barrel 1, and barrel 2. It contains an initiation peptide of 37 amino acids that 
confines the entrance of the substrate to the dynamic site cysteine. 
The B-subunit is a measured protein made out of 10 repeated Sushi or glycoprotein-1 
domains 16, 17. Each Sushi areas contains 2 disulfide bridges that support its tertiary structure, 
adding up to a sum of 40 cysteine deposits and 20 disulfide connects in the developed B-subunit 
protein. The primary function of the B-subunit is the stabilization and transport of the 
hydrophobic A-subunit in the aqueous environment of human plasma. Elevated factor XIII 
levels causes an illness called atherosclerosis, though dimethylbiguanide (metformin) 
interferes with component XIII initiation and with fibrin polymerization. At the point when the 
illness is treated with metformin more than a 12 week period, component XIIIB antigen and 
reactivity levels were diminished and it controls the infection. 
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5.2  Conclusion 
Coronary heart illness and stroke rate is higher in south and eastern Indian populaces. 
The cardiovascular system is mainly damaged due to one of the membrane bound protein, 
where a wide range of evidence indicates that Coagulation factor XIII B is important in the 
complement and coagulation cascade of vascular complications. Human Coagulation factor 
XIII B is supplement framework and its effect was seen in atherosclerosis, myocardial 
infarction and so on. Keeping in mind the end goal to find strong inhibitors subsequently an in 
silico work has been completed to distinguish powerful inhibitors for the protein. In the present 
study proteomic analysis, phylogenetic analysis, docking was performed to Coagulation factor 
XIII B. In Proteomic analysis examples, BLOCKS, catalytic domains were predicted. 
Coagulation factor XIII B with the other 29 cardiovascular disease causing genes, delineated 
close relationship among them justifying role of Coagulation factor XIII B as a cardiovascular 
protein. Docking was performed and results were analyzed where 6 potential leads were 
identified. Among them lead 1 molecule with least docking score -5.321 was identified as best 
lead. It is a new immunosuppressive drug; it has fewer side effects. In silico pharmacokinetics 
study for the proposed two leads are within the range of parameters involved in both 
pharmacological and ADME properties. The lead 1 molecule can inhibit the elevated levels of 
Coagulation factor XIII B efficiently during the cardiovascular disease condition. Hence, lead 
1 act as an effective drug against Coagulation factor XIII B if synthesized and validated in 
animal models. 
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